Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives
Medicina · 03.04.2026 · 62 (4) · 683
DOI: 10.3390/medicina62040683 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicina, online erschienen am 03.04.2026. Verfasst von Bogdan Oprea. Beteiligte Einrichtung: Department 1-Histology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Petru Rares, 2, 200349 Craiova, Romania. Hauptthemen laut MEDLINE: Stomach Neoplasms, Immunohistochemistry, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 248 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: Immunohistochemistry (IHC) is a keystone in gastric cancer (GC) management, allowing treatment customization, including for advanced or metastatic diseases. This review aims to evaluate the critical role of IHC markers, analyzing their efficiency in molecular subclassification and prediction of response to gastric cancer-targeted therapies, while also describing state-of-the-art IHC techniques and perspectives.
Results
The major challenges for the GC management were structured in two main sections, as follows: (i) the current paradigm of gastric neoplasia diagnosis, which includes subsections related to the methodological and morphological foundations, the epidemiological dynamics, and risk factors, as well as differential diagnosis of poorly differentiated tumors; and (ii) the progress in 3,3′-diaminobenzidine (DAB) application and advanced reagents in gastric cancer immunohistochemistry.
Discussion
Considering the role of IHC and DAB, the following topics were successively addressed in seven sections: GC key biomarkers, such as human epidermal growth factor receptor 2 (HER2), programmed death-ligand 1 (PD-L1), and DNA replication mismatch repair (MMR) system, allow direct correlation between tissue morphology and protein expression; intestinal and gastrointestinal differentiation markers; emerging and aggressive histological subtypes; epithelial–mesenchymal transition, E-cadherin, and the process of tumor budding; implementation of innovative procedures in gastric cancer immunohistochemistry; and automation, quality control, and sustainability in the pathology laboratory. Perspectives: The main directions were focused on the integration of artificial intelligence (AI) algorithms for digital quantification of the IHC signal and also on the expansion of panels to new targets, such as Claudin 18.2 (CLDN 18.2), which redefines treatment approaches in advanced stages.
Conclusions
Although faced with technical and biological limitations, immunohistochemistry remains indispensable in modern gastric oncology. The evolution towards digital pathology and the refinement of scoring criteria will transform IHC from a complementary test into a visual tool that is essential for personalizing oncological treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department 1-Histology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Petru Rares, 2, 200349 Craiova, Romania.
Zitieren
APA
Oprea, B. (2026). Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives. Medicina, 62(4), 683. https://doi.org/10.3390/medicina62040683
Vancouver
Oprea B. Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives. Medicina. 2026;62(4):683. doi:10.3390/medicina62040683
BibTeX
@article{Oprea2026,
author = {Oprea, Bogdan},
title = {Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives},
journal = {Medicina},
year = {2026},
volume = {62},
number = {4},
pages = {683},
doi = {10.3390/medicina62040683}
}
EUVIMED